OrthoPediatrics (NASDAQ:KIDS) Shares Up 10.3% – Time to Buy?

OrthoPediatrics Corp. (NASDAQ:KIDS) was up 10.3% during mid-day trading on Monday . The stock traded as high as $20.33 and last traded at $20.1950. Approximately 82,982 shares traded hands during trading, a decline of 33% from the average daily volume of 124,031 shares. The stock had previously closed at $18.31.

Wall Street Analysts Forecast Growth

KIDS has been the subject of several recent analyst reports. Wall Street Zen cut OrthoPediatrics from a “hold” rating to a “sell” rating in a research note on Saturday, December 20th. Stifel Nicolaus lowered their target price on shares of OrthoPediatrics from $32.00 to $20.00 and set a “buy” rating on the stock in a research note on Friday, October 10th. Needham & Company LLC dropped their price target on shares of OrthoPediatrics from $42.00 to $26.00 and set a “buy” rating on the stock in a research report on Wednesday, October 29th. BTIG Research reiterated a “buy” rating and issued a $23.00 price objective on shares of OrthoPediatrics in a report on Wednesday, October 29th. Finally, JMP Securities lowered their price objective on shares of OrthoPediatrics from $35.00 to $25.00 and set a “market outperform” rating on the stock in a research note on Friday, October 10th. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $24.00.

OrthoPediatrics Stock Performance

The company’s 50-day moving average price is $17.79 and its two-hundred day moving average price is $19.06. The company has a market cap of $462.42 million, a P/E ratio of -9.46 and a beta of 1.09. The company has a current ratio of 7.40, a quick ratio of 3.52 and a debt-to-equity ratio of 0.28.

OrthoPediatrics (NASDAQ:KIDS) last released its earnings results on Tuesday, October 28th. The company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.02. The business had revenue of $61.25 million during the quarter, compared to analyst estimates of $63.63 million. OrthoPediatrics had a negative net margin of 20.06% and a negative return on equity of 6.86%. As a group, equities analysts forecast that OrthoPediatrics Corp. will post -0.93 earnings per share for the current year.

Hedge Funds Weigh In On OrthoPediatrics

Hedge funds and other institutional investors have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in OrthoPediatrics by 6.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company’s stock worth $246,000 after buying an additional 645 shares during the period. Russell Investments Group Ltd. raised its holdings in shares of OrthoPediatrics by 433.1% during the third quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock valued at $26,000 after acquiring an additional 1,139 shares during the period. BNP Paribas Financial Markets lifted its position in shares of OrthoPediatrics by 60.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock valued at $61,000 after acquiring an additional 1,235 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its stake in OrthoPediatrics by 12.4% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 15,901 shares of the company’s stock worth $342,000 after purchasing an additional 1,753 shares during the period. Finally, Caption Management LLC acquired a new position in OrthoPediatrics in the 3rd quarter worth approximately $54,000. Institutional investors and hedge funds own 69.05% of the company’s stock.

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.